Jean-Pierre Bizzari - 23 Aug 2023 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ John Hamill, as Attorney-in-Fact
Issuer symbol
APRE
Transactions as of
23 Aug 2023
Net transactions value
$0
Form type
4
Filing time
24 Aug 2023, 21:47:00 UTC
Previous filing
09 May 2023
Next filing
02 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +12,500 $0.000000 12,500 23 Aug 2023 Common Stock 12,500 $3.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options shall vest in full on the two year anniversary of the grant date, subject to the reporting person's continued service on the Issuer's board of Directors through and including the applicable vesting date.